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Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily 
dependent on the severity of hypertension, and to compare the effectiveness of two antihypertensive drugs with 
opposite effects on the renin-angiotensin system [the diuretic, indapamide sustained release (SR), and an 
angiotensin-converting enzyme inhibitor, enalapril] in reducing microalbuminuria. 
Design A multinational, multicentre, controlled, double-blind, double-dummy, randomized, two-parallel-groups 
study over 1 year. 
Methods After a 4-week placebo run-in period, 570 patients (ages 60.0 ± 9.9 years, 64% men) with type 2 
diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure 
(DBP) < 110 mmHg], and persistent microalbuminuria (20-200 µg/min) were allocated randomly to groups to 
receive indapamide SR 1.5 mg (n = 284) or enalapril 10 mg (n = 286) once a day. Amlodipine, atenolol, or both 
were added, if necessary, to achieve the target blood pressure of 140/85 mmHg. 
Results There was a significant reduction in the urinary albumin : creatinine ratio. Mean reductions were 35% 
[95% confidence interval (Cl) 24 to 43] and 39% (95% Cl 30 to 47%) in the indapamide SR and enalapril 
groups, respectively. Equivalence was demonstrated between the two groups [1.08 (95% Cl 0.89 to 1.31%);          
P = 0.01]. The reductions in mean arterial pressure (MAP) were 16.6 ± 9.0 mmHg for the indapamide SR group 
and 15.0 ± 9.1 mmHg for the enalapril group (NS); the reduction in SBP was significantly greater (P= 0.0245 ) 
with indapamide SR. More than 50% of patients in each group required additional antihypertensive therapy, with 
no differences between groups. Both treatments were well tolerated. 
Conclusions Indapamide-SR-based therapy is equivalent to enalapril-based therapy in reducing 
microalbuminuria with effective blood pressure reduction in patients with hypertension and type 2 diabetes. 
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INTRODUCTION 
Patients with type 2 diabetes display a serious cardiovascular risk profile [1] that is aggravated by hypertension 
[2]. Microalbuminuria [i.e. albumin excretion rate (AER) between normal values and those giving positive 
dipstick test results for proteinuria [3]] adds a two- to four-fold risk for cardiovascular and renal events [4-6] in 
these patients. Reduction in microalbuminuria may signal improvement in prognosis [7]. In this respect, drugs 
able to block the effectiveness of the renin-angiotensin system (RAS) are of special interest. The angiotensin-
converting enzyme inhibitors (ACEI) reduce microalbuminuria and prevent or reduce the progression of diabetic 
nephropathy in patients with type 1 diabetes [8,9]. In patients with type 2 diabetes, ACEI, as compared with 
placebo, reduce the progression of microalbuminuria and prevent cardiovascular diseases [7], and angiotensin II 
type 1 (AT1) receptor antagonists reduce microalbuminuria and prevent end-stage renal failure [10,11]. 
However, the respective contributions of ameliorations in systemic blood pressure and in renal haemodynamics 
to the benefits provided by the blockers of the RAS need to be examined in diabetic patients. The predominant 
role of the RAS in the genesis of microalbuminuria has been demonstrated in patients with type 1 diabetes, 
normotension and microalbuminuria, in studies in which the blood pressure was reduced to the same extent by 
two drugs having opposite effects on RAS effectiveness: hydrochlorothiazide, a diuretic, and enalapril, an ACEI. 
Microalbuminuria was reduced by enalapril, but not by hydrochlorothiazide over 1 year [12]. A large body of 
evidence supports the use of ACEI to treat nephropathy in type 1 diabetes [13]. Conversely, the special benefits 
of RAS blockade compared with those provided by blood pressure reduction by itself are less clear in patients 
with type 2 diabetes with microalbuminuria. For instance, the reductions in clinic blood pressure seen in the 
participants in the Heart Outcomes Prevention Evaluation (HOPE) study and the Microalbuminuria, 
Cardiovascular and Renal Outcomes substudy of the HOPE trial [7,14] were small in those given 10 mg ramipril 
in the evening compared with those on placebo, but the night-time blood pressure was clearly reduced by 
ramipril as compared with placebo in the subgroup of participants who underwent ambulatory blood pressure 
monitoring (ABPM) [15]. Also, it is well known that conventional antihypertensive drugs reduce a high AER in 
patients with essential hypertension without diabetes [16]. In this respect, a large proportion of patients with type 
2 diabetes with microalbuminuria also display permanent hypertension [17]. Thus it remains debatable whether 
microalbuminuria is a consequence of the severity of essential hypertension or of abnormal renal 
haemodynamics as a result of diabetes in type 2 diabetic patients with essential hypertension. 
To study this issue further, we compared the efficacy of two antihypertensive drugs with opposite effects on the 
RAS [indapamide sustained release (SR), a diuretic, and enalapril, an ACEI] in reducing microalbuminuria in 
type 2 diabetic patients with hypertension. In this 1-year, double-blind study, we hypothesized an equivalent 
effect of the two study drugs in reducing microalbuminuria. 
PATIENTS AND METHODS 
The design of this study has been published in detail previously [18]. Briefly, it was a multinational, double-
blind, double-dummy, two-parallel-groups, randomized, 1-year study comparing indapamide SR (indapamide 
1.5 mg in a sustained release formulation) with enalapril 10 mg per day. After a 4-week placebo run-in period, 
participants were allocated randomly to groups to receive orally, once-daily at breakfast, either indapamide SR 
or enalapril and their matched placebo, for a 52-week active treatment period. Visits were performed after 6, 12, 
18, 24, 36 and 52 weeks. From the sixth week of treatment, additional, open-label antihypertensive treatment 
was prescribed if target blood pressure was not achieved [systolic blood pressure (SBP) ≤ 140mmHg and 
diastolic blood pressure (DBP) < 85 mmHg] in four steps separated by 6-week intervals: amlodipine 5 mg once 
daily, then amlodipine 10 mg once daily, then amlodipine 10 mg plus atenolol 50 mg once daily, and finally 
amlodipine 10 mg plus atenolol 100 mg once daily. Adaptation of the antidiabetic treatment, including insulin, 
and potassium supplements (if kalaemia was less than 3.5 mmol/1) were allowed from the sixth week of the 
study. 
During the placebo period, eligibility determined by the presence of persistent microalbuminuria was assessed as 
an AER between 20 and 200 µg/min on at least two of three overnight urine collections. During the active 
treatment period, AER was assessed on overnight urine collected every 12 weeks until completion of the study. 
During each visit, the clinic blood pressure was measured by the investigators as described below. ABPM was 
performed in volunteer centres before random allocation to groups and at the end of the study. 
Weight was measured at selection and at each visit from week 0 to week 52.µ 
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A standard 12-lead electrocardiogram (ECG) was recorded at week 0 and week 52 to screen for rhythm, 
conduction and repolarization disorders. 
The following laboratory tests were performed before random allocation to groups and at the end of the study: 
fasting plasma sodium, potassium, creatinine, uric acid, glucose, glycated haemoglobin (HbA1c), triglycerides, 
total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Urinary creatinine, sodium 
and potassium were measured on overnight urine collections. 
Spontaneous reporting of adverse events was recorded at each visit. 
Patients 
Patients were recruited at 231 active centres (private or public hospitals, general practitioners or specialists), in 
18 countries (see Appendix) between April 1997 and January 2000. Inclusion criteria were: men and women 
aged between 35 and 80 years, with type 2 diabetes [19], persistent microalbuminuria and essential hypertension. 
Diabetes was required to be controlled by diet with or without one or more oral antidiabetic treatment, 
unchanged for at least 3 months. At selection and at inclusion, in those receiving placebo, hypertension was 
defined as patients having SBP 140-180 mmHg and DBP < 110 mmHg. For selection, microalbuminuria had to 
be documented within the previous year. For inclusion, persistent microalbuminuria was defined as described 
above. 
The main criteria for exclusion from the study were: severe hypertension, body mass index > 40 kg/m2, 
ventricular rhythm disorders on ECG, urinary tract infection, haematuria or leucocyturia, plasma creatinine > 
150 µmol/l, kalaemia < 3.5 mmol/1 or > 5.5 mmol/l, uric acid > 536 µmol/l, treatment with potassium 
supplement or insulin and poor placebo compliance during the run-in period. Previously known intolerance to 
ACEI or diuretics was also a criterion for exclusion. The study was performed in accordance with Good Clinical 
Practice and approved by Ethics Committees of each country. Each patient gave his or her written informed 
consent before enrolment. 
Investigations 
Timed overnight urine samples were stored at 4-8°C, and sent by express carrier to a central laboratory 
(Biochemistry Department, University Hospital Angers, France). After urine screening for leucocyturia and 
haematuria using dedicated dipsticks (Multistix R; Bayer Diagnostics, Puteaux, France), urinary albumin was 
measured by nephelometry [20] (assay sensitivity 2 mg/l; inter- and intra-assay coefficients of variation 4 and 
3%, respectively). 
The central laboratory for all other biological analyses during the study was Institut Pasteur, Lille, France. Apart 
from haematology (Technicon H3; Bayer) and HbA1c (Biorad kit manufacturer), all other parameters were 
measured using conventional methods on a Hitachi 917 analyser. 
Creatinine was measured using the Jaffe method. Creatinine clearance was assessed with the Cockcroft formula 
[21]. LDL was calculated using the Friedwald formula. 
Systolic and diastolic blood pressures were measured by the investigators using a mercury sphygmomanometer 
with a cuff sized to the patient's arm as recommended [22], in the morning before drug intake, after the patient 
had undergone a 10-min period of rest in the supine position (the mean of three measurements was calculated), 
then after they had been standing for 3 min. 
For 24-h ABPM, only validated devices according to the British Hypertension Society or the American 
Association for the Advancement of Medical Instrumentation (grade B/B at least) [23-25] were accepted for use 
in this study, and the following devices were used: SpaceLabs 90202, 90207 and 90217 and Accu-tracker II. 
Examination was carried out on a normal working day, the last day of the placebo run-in period (week 0) and 
after 1 year of treatment (week 52), using the same recorder for the same patient, on the same arm. The drug was 
taken just after the recorder was fitted in the morning. Blood pressure was measured every 15 min during the  
24-h period, or at least one measurement every 15 min in the daytime (0700 to 2200 h) and one measurement 
every 30 min at nighttime (2200 to 0700 h) [26,27]. 
All ABPM recordings were edited by the investigators and sent to the Central Committee for validation by an 
expert. Examination was validated if apparatus was fitted between 0800 and 1100 h, duration of the recording 
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was 24 h including drug intake and at least 75% of valid measurements were present. Absence of two 
consecutive hourly averages, or missing data for the first and 24th hours were verified. 
Assessment of safety was based mainly on analysis of adverse events, ECG parameters, body mass index and 
biochemical parameters. 
Statistical analysis 
Statistical efficacy analysis was performed on the intention-to-treat population, defined as all randomly assigned 
patients exposed to treatment. The primary objective of the analysis was to test the hypothesis of one-sided 
equivalence (non-inferiority) of indapamide SR in comparison with enalapril on microalbuminuria evaluated by 
urinary albumin: creatinine ratio (UACR), AER and fractional albumin clearance, calculated as: urinary albumin 
concentration × plasma creatinine concentration/urinary creatinine concentration × plasma albumin 
concentration. The secondary objectives were to evaluate the antihypertensive activity assessed by variations 
from baseline of supine SBP, DBP, MAP (calculated as one-third of SBP plus two-thirds of DBP), and safety. 
The analysis of albuminuria after log transformation was determined using a limit of non-inferiority not greater 
than 35% of the value in the enalapril group at the final visit, this being the assumed clinically significant 
difference. It has been calculated that this study requires at least 253 patients per treatment group with a standard 
deviation of log (albuminuria) estimated to be 0.82 [28] with α = 2.5% and a power of 80%. Taking into account 
expected withdrawals from the study, an additional 10% of patients were included. Microalbuminuria parameters 
were logarithmically transformed and are presented as the geometric means (Gmean) with their 95% confidence 
intervals (CI). 
All analyses were adjusted on baseline value for each parameter. Changes from baseline in microalbuminuria 
and blood pressure were compared between groups with a linear model for analysis of covariance. SAS software 
8.1 (SAS Institute, Cary, North Carolina, USA) was used. 
RESULTS 
Of the 1223 patients enrolled, 570 patients were allocated randomly to groups (Fig. 1) and 653 were not eligible, 
77% because urinary analyses performed in the central laboratory did not confirm microalbuminuria. 
Two hundred and forty-seven (87%) and 255 (89%) patients completed the study at week 52 in the indapamide 
SR and in the enalapril groups, respectively. One patient allocated randomly to a study group was never exposed 
to the study drug, so there were a total of 569 patients assessable. None of the included patients was lost to 
follow-up during the study. Sixty-seven patients discontinued the treatment, including: three who died (one 
sudden death and one myocardial infarction in the indapamide SR group and one cardiac arrest in the enalapril 
group), 29 for medical reasons (one uncontrolled hypertension, one coughing, four cerebrovascular disorder, two 
angina pectoris, two myocardial infarction, one dizziness, one uterine carcinoma, one hepatic neoplasm and one 
kidney stone in the indapamide SR group; three uncontrolled hypertension, two coughing, two lymphocytic 
leukaemia, one fatigue, one headache, one thrombosis of retinal vein, one vertigo, one alcohol intolerance, one 
anorexia, one diabetes worsened and one appendicitis in the enalapril group); 20 for non-medical reasons, mainly 
the patient's decision (12 indapamide SR/8 enalapril); and 15 for major procedural deviations (eight indapamide 
SR/ seven enalapril). 
From the sixth week of study treatment, an adjunctive therapy for hypertension was taken by 305 patients (143 in 
the indapamide SR group and 162 in the enalapril group). The distribution of patients treated by monotherapy/+ 
amlodipine alone/+ atenolol alone/+ amlodipine + atenolol was similar in the two groups: 140/112/8/23 patients 
in the indapamide SR group and 124/121/7/34 patients in the enalapril group (P = 0.322). The mean global 
compliance with study treatments through the duration of the study was similar in the two groups: 98.1 and 
98.5%, respectively. The baseline characteristics of the patients were similar in the two groups (Table 1). 
The results of the analysis of efficacy criteria are shown in Figure 2 and Table 2. 
At the follow-up visit, there was a significant decrease in UACR of 35 and 39% in the indapamide SR and the 
enalapril groups, respectively. The one-sided equivalence of treatment based on indapamide SR was 
demonstrated statistically (P = 0.0121), with a ratio of 1.08 (95% CI 0.89 to 1.31) when compared with 
treatment based on enalapril. 
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At the last observation, in the indapamide SR group, 112 patients (40%) had improved to normoalbuminuria 
(UACR < 2.5 mg/mmol in men and < 3.5 mg/mmol in women), 145 (51%) maintained microalbuminuria 
(UACR 2.5-25 mg/mmol in men and 3.5-25 mg/mmol in women), and 26 (9%) had deteriorated to macroalbu-
minuria (UACR > 25 mg/mmol in men and women). In the enalapril group, the values were 120 (42%), 148 
(52%) and 18 patients (6%), respectively (P = 0.418; χ2 test). 
Both treatments showed antihypertensive efficacy (Table 2). There was a significant decrease (P < 0.001) in 
SBP, DBP and MAP in both treatments between baseline and endpoint. The change in MAP was not different 
between the two groups: -1.19 mmHg (95% CI -2.55 to 0.16), with a decrease of 16.6 ± 9.0 mmHg with 
indapamide SR and 15.0 ±9.1 mmHg with enalapril. In addition, supine SBP was significantly more reduced           
(P = 0.0245) in the indapamide SR group (-23.8 ± 13.3 mmHg) than in the enalapril group (-21.0 ± 14.3 
mmHg), but DBP was not (P = 0.3395): -13.0 ± 9.3 mmHg compared with -12.1 ± 8.6 mmHg, respectively. 
This finding was confirmed in the subgroup of 99 patients who underwent a 24-h ABPM, with a nonsignificant 
mean difference of MAP over 24 h between the two treatment strategies of -0.63 mmHg (95% CI -3.57 to 2.31; 
Fig. 3). 
Renal function did not change in either treatment group (Table 2). 
We calculated the relationship between change in the supine SBP, DBP and MAP and change in the UACR from 
the beginning to the end of the study for the two treatment groups. There was no difference between groups (data 
not shown). 
The two treatment regimens were generally well tolerated and no unexpected adverse events occurred. 
Three instances of orthostatic hypotension were reported: one in the indapamide SR group and two in the 
enalapril group. Results concerning the urinary and plasma biochemistry are shown in Table 3. Among all 
biological parameters assessed during the study, a difference between groups was observed only for serum 
potassium, uric acid, total cholesterol and HbA1c (Table 3). Twenty-nine patients (10.2%) in the indapamide SR 
group and three (1.0%) in the enalapril group had at least one emergent serum potassium concentration < 3.4 
mmol/l. Only seven patients (2.5%) in the indapamide SR group and 10 patients (3.5%) in the enalapril group 
required insulin therapy during the year of treatment. 
Fig. 1 
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Table 1-  Baseline characteristics of patients 
Demographics INDSR (n = 283) ENL (n = 286) 
Age (years) 60.8 (9.9) 59.2 (9.9) 
Men/women (%) 66/34 63/37 
White/Black/Asian/other (%) 85/4/3/8 86/5/2/7 
Body mass index (kg/m2) 29.3 (4.0) 29.8 (4.2) 
Smokers/ex-smoker/non-smoker (%) 13/24/63 15/22/63 
Diabetes duration (months) 100.0 (81.5) 97.6 (81.5) 
Family history of diabetes (%) 42 49 
Oral hypoglycaemic agenta: 0/1/≥2 (%) 13/49/38 9/45/46 
HbA1c (%) 7.49 (2.00) 7.71 (1.90) 
Hypertension duration (months) 107.4 (93.2) 92.7 (83.2) 
Family history of hypertension (°/o) 38 41 
Hypertension previously treated (°/o) 78 73 
Values are mean ± SD or number. aOral hypoglycaemic agent: 0 = diet alone; 1 = one agent; ≥2 = at least two at random allocation to groups. 
IND SR, indapamide sustained release; ENL: enalapril; HbA1c, glycated haemoglobin. 
 
Fig. 2- Albumin excretion rate (AER; semi-log scale) and mean arterial pressure (MAP; mean ± SD) in the two 
treatment groups (intention-to-treat populations) over the 52-week duration of the study. Bars in box plots 
correspond, from lower to upper, to 10%, 25%, 50% (median), 75% and 90% of the values and the extreme 
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Table 2- Evolution of efficacy criteria 
Criteria   INDSR(n = 283) ENL (n = 286) Inter-group comparison P 
Baseline Gmean (Q1, Q3) 6.16 (3.50, 10.33) 6.17 (3.33, 10.97)   
Final Gmean (Q1, Q3) 4.03 (1.67, 9.00) 3.74 (1.40, 8.00) 1.08 (0.89 to 1.31) 0.0121§ 
UACR (mg/mmol)
 
% Decline Gmean (95% CI) 35 (24 to 43) 39 (30 to 47)   
Baseline Gmean (Q1, Q3) 58.42 (33.27, 96.77) 57.97 (34.07, 106.5)   
Final Gmean (Q1, Q3) 36.95 (13.90, 92.42) 32.10 (12.44, 72.22) 1.15 (0.93 to 1.41) 0.0616§ 
AER (µg/min) 
 
% Decline Gmean (95% CI) 37 (26 to 46) 45 (36 to 52 )   
Baseline Mean (SD) 91.5 (29.5) 93.4 (29.2)   
Final Mean (SD) 87.9 (29.8) 89.4 (28.6)   
Creatinine 
clearance (ml/min)
∆ Decrease Mean (95% CI) -3.6 (-4.93 to -2.30) -4.0 (-5.21 to -2.81) 0.26 (-1.48 to 2.00) 0.7701‡ 
Baseline Gmean (Q1, Q3) 10.98 (6.21, 19.30) 11.06 (6.04, 20.06)   
Final Gmean (Q1, Q3) 7.57 (3.15, 17.78) 6.92 (2.70, 15.87) 1.09 (0.89 to 1.33) 0.01 66§ 
Fractional albumin 
clearance 
(10-6) % Decline Gmean (95% CI) 31 (21 to 41) 37 (28 to 45)   
Baseline Mean (SD) 161.1 (10.8) 160.2 (10.8)   
Final Mean (SD) 137.3 (12.0) 139.3 (14.3)   
Supine SBP 
(mmHg) 
∆ Decrease Mean (95% CI) -23.8 (-25.4 to -22.2) -21.0  (-22.6 to -19.3) -2.34 (-4.38 to -0.30) 0.0245‡ 
Baseline Mean (SD) 94.0 (6.9) 93.5 (6.1)   
Final Mean (SD) 81.0 (8.1) 81.4 (7.9)   
Supine DBP 
(mmHg) 
 ∆ Decrease Mean (95% CI) -13.0 (-14.1 to -11.9) -12.1 (-13.1 to -11.1) -0.62 (-1.90 to 0.65) 0.3395‡ 
Baseline Mean (SD) 116.3 (6.3) 115.7 (5.7)   
Final Mean (SD) 99.7 (8.1) 100.7 (8.9)   
Supine MAP 
(mmHg) 
∆ Decrease Mean (95% CI) -16.6 (-17.7 to -15.5) -15.0 (-16.1 to -14.0) -1.19 (-2.55 to 0.16) 0.0847‡ 
Within-group variations in microalbuminuria are expressed as % Decline; within-group variations in blood pressure and creatinine clearance are expressed as ∆ Decrease. IND SR, indapamide sustained release; ENL, 
enalapril; UACR, urinary albumin creatinine ratio; Gmean, geometric mean; Q1, first quartile; Q3, third quartile; CI, confidence interval; AER, albumin excretion rate. § One-sided equivalence test: one-tailed Student's 
Mest for independent samples (α = 2.5%) after adjustment on baseline studied on the log-transformed values of albuminuria with a limit of non-inferiority of 30% - that is, 1.35 antilog limit; ‡ difference test: two-tailed 
Student's Mest for independent samples (α = 5%) on adjusted mean difference.
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Fig. 3 Mean changes over 24 h in systolic (SBP), diastolic (DBP) and mean arterial (MAP) blood pressures 
(ambulatory blood pressure monitoring). IND SR, indapamide sustained release; ENL, enalapril. 
 
Table 3- Evolution of biochemistry parameters 
INDSR ENL Parameters 
 
 n Baseline Final n Baseline Final 
Changes 





Na (mmol/l) 273 139.8 ±2.2 138.9 ±2.4 280 139.8 ± 2.6 138.9 ± 2.7 -0.06 = 0.7348 
K (mmol/l) 270 4.4 ± 0.4 4.2 ± 0.4 278 4.4 ± 0.4 4.5 ± 0.4 -0.32 < 0.001 
Nau (µmol/min) 261 169.6 ± 97.7 199.2 ±115.0 269 173.2 ± 91.2 165.6 ± 90.8 34.87 < 0.001 
Ku (µmol/min) 262 48.7 ± 26.0 55.5 ± 34.3 269 49.8 ± 29.2 51.5 ±8.0 4.31 = 0.1622 
Uric acid (µmol/l) 251 335.6 ± 76.8 365.2 ± 94.8 262 334.9 ± 88.5 340.8 ± 95.2 23.94 < 0.001 
Total chol. (mmol/l) 236 5.2 ± 1.0 5.4 ±1.1 251 5.4 ± 1.0 5.3 ±1.1 0.16 = 0.0425 
HDL chol. (mmol/l) 236 1.1 ± 0.3 1.1 ± 0.3 251 1.2 ± 0.3 1.2 ± 0.3 0.01 = 0.4750 
LDL chol. (mmol/l) 210 3.3 ± 0.8 3. 3 ± 0.9 232 3.4 ± 0.9 3.3 ±0.9 0.06 = 0.3031 
Triglycerides (mmol/l) 235 2.1 ± 1.5 2.4 ± 2.1 251 1.9 ± 1.4 2.1 ± 1.9 0.21 = 0.1476 
Glucose (mmol/l)b 249 8.9 ± .7 9.7 ± 3.9 261 9.3 ± 3.4 9.6 ± 3.5 0.30 = 0.2603 
HbA1c (%) 230 7.4 ± 2.0 8.1 ± 2.3 244 7.7 ± 1.9 7.9 ± 2.1 0.50 = 0.0006 
IND SR, indapamide sustained release; ENL, enalapril; Na, plasma sodium; K, plasma potassium; NaU urinary sodium flow; KU urinary 
potassium flow; HDL, LDL, high- and low-density lipoproteins; chol., cholesterol. alnter-group comparison; bfasting plasma glucose. 
 
DISCUSSION 
In this study, we found that microalbuminuria in patients with type 2 diabetes with hypertension was reduced by 
an equivalent amount by two antihypertensive drugs that have opposite effects on the RAS: the diuretic, 
indapamide SR, and the ACEI, enalapril. These results support a predominant role of high systemic blood 
pressure in the development of microalbuminuria in this population of patients. 
In a 1-year international study comparing it with enalapril, indapamide SR reduced SBP/DBP by 25.2/12.8 
mmHg [29] and enalapril reduced them by 24.5/ 12.4 mmHg. In a comparative study of enalapril and 
bendrofluazide [30], enalapril reduced SBP/DBP by 25.0/16.0 mmHg. In the case of enalapril, an even smaller 
dose (5 mg/day) was able to reduce microalbuminuria in similar patients [31], and 10 mg/day of enalapril -the 
usual dose tested in the development of the drug [32] -was the dose used to prevent the doubling of serum 
creatinine in normotensive patients with type 2 diabetes with baseline microalbuminuria over 7 years [33]. 
The number of patients enrolled in this study was calculated to test one-sided equivalence between drugs on the 
primary outcome - that is, microalbuminuria. Patient compliance with treatment was excellent (98.3%). The 
proportion of patients requiring additional antihypertensive drugs (amlodipine, atenolol, or both) was more than 
50%, and similar in both groups. The study can be considered to be a comparison between an antihypertensive 
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strategy based on a diuretic and another based on an ACEI. 
The reductions in MAP were equivalent between drugs, although SBP was reduced more with indapamide SR 
than with enalapril. Interestingly, analysis of ABPM in a subset of patients showed no inter-group difference for 
daytime/night-time or SBP/DBP/MAP. As MAP reflects the pressure transmitted to the patient's renal 
circulation, the equivalent effect of indapamide SR and of enalapril on microalbuminuria could not be explained 
by different antihypertensive effects of the two drugs. Urinary albumin excretion also depends on the amount of 
albumin filtered through the glomerular barrier. In the short term, ACEIs may reduce the glomerular filtration 
rate (GFR) more than other antihypertensive drugs [34], thereby accounting for a more pronounced anti-
albuminuric effect. The reductions in UACR and in fractional albumin clearance, which both reflect the 
glomerular permeability to albumin by taking into account glomerular filtration rate, were equivalent with the 
two drugs. Thus we can assume that indapamide SR and enalapril strategies were equally effective with respect 
to microalbuminuria and glomerular permeability to albumin in these patients with type 2 diabetes with 
permanent hypertension. 
The NESTOR study was a 1-year study - a duration sufficient for evaluation of the efficacy of an 
antihypertensive drug on microalbuminuria in diabetic patients. In a study of the same duration, in 21 
normotensive patients with type 1 diabetes, the superiority of enalapril to hydrochlorothiazide with respect to 
microalbuminuria was demonstrated [12]. Nielsen et al. [35] showed that proteinuria in patients with type 2 
diabetes with nephropathy was reduced more by lisinopril than by atenolol, although GFR was protected equally 
by both drugs after 4 years [36]. The findings of these studies are consistent with the hypothesis that ACEIs 
reduce microalbuminuria better than conventional drugs for a given reduction in blood pressure and support the 
predominant role of the renal haemodynamics in the constitution of diabetic nephropathy. Here, we report that 
the reduction in microalbuminuria in patients with type 2 diabetes with permanent hypertension was primarily 
dependent on the reduction in systemic blood pressure. This interpretation is consistent with the findings of the 
hypertension study of the UK Prospective Diabetes Study Group [37]: the magnitude of the reduction in 
microalbuminuria or proteinuria onset was not different with captopril or with atenolol, compared with the 
conventional strategy. Also, our data fit with recent histological findings showing minimal glomerular lesions in 
patients with type 2 diabetes with microalbuminuria and hypertension [38], similar to those described in 'benign' 
hypertension many years ago [39]. 
Both treatments were well tolerated over the 1 year of follow-up. Some biological differences between groups 
reached a significant level. For plasma potassium concentration, the difference observed between the indapa-
mide SR and enalapril groups is consistent with previous findings showing that ACEIs increase the potassium 
concentration, whereas diuretics decrease them. Concerning lipid profiles, only the total cholesterol 
concentration was significantly increased in the indapamide SR group; HDL, LDL and triglycerides 
concentrations were not. Whether such slight biological changes affect the cardiovascular prognosis in the long 
term is highly questionable in light of the recent data from the Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT) study [40]. 
Despite the lack of change in fasting plasma glucose concentration, the absolute difference between groups for 
changes in HbA1c was 0.5% in favour of enalapril. However, HbA1c was not monitored throughout the study, but 
measured only at baseline and at 1 year of treatment. The modalities of diabetes control and antidiabetic strategy 
were decided freely by each investigator according to the local guidelines and national recommendations. In this 
respect, there were three fewer patients receiving indapamide SR than receiving enalapril among the 17 whose 
treatment was changed to insulin during the study. The 0.5% inter-group difference for HbA1c in favour of 
enalapril against indapamide SR probably conferred no major excess cardiovascular risk to participants receiving 
indapamide SR. An inter-group difference of 0.9% HbA1c led to a 25% (95% CI 7 to 40%) risk reduction for 
microvascular events over 10 years during the UKPDS glucose trial, but there was no inter-group difference for 
stroke, heart failure or diabetes-related mortality [41]; only the risk for myocardial infarction was slightly 
reduced over 10 years [41]. The current trial was not designed   to   test   cardiovascular outcomes based on 
glycaemic strategies. It was a 1-year trial based on changes in AER, a surrogate endpoint that predicts high risk 
for cardiovascular and renal diseases in such patients [4-7]. 
Finally, this is the first randomized study over 1 year to test the effectiveness of a diuretic-based treatment on 
microalbuminuria in patients with type 2 diabetes with hypertension. Indapamide SR, a diuretic, was as effective 
as enalapril, a drug with a proven efficacy in this domain.The efficacy of indapamide SR may rely on a 
pathophysiological rationale, as diabetic patients are characterized by an increase in systemic sodium, which can 
favour hypertension. Diuretic drugs have proven their utility in essential hypertension, including in patients with 
diabetes [42]. ALLHAT [40] confirmed that, in the long term, diuretics are as effective as ACEIs for the primary 
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prevention of cardiovascular disease in hypertensive individuals at high cardiovascular risk. In line with the Joint 
National Committee 7 Report [43] and European Society of Hypertension-European Society of Cardiology 2003 
[44] recommendations, this finding is consistent with the use of indapamide SR as first-line treatment in 
hypertensive type 2 diabetic patients with microalbuminuria. 
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